Today, Amplia has announced a $12.4million capital raising via Placement and Entitlement offer.
Proceeds from this capital raise are forecast to fund Amplia’s plans to conduct a Phase 2 clinical trial of AMP945 in patients with pancreatic cancer, including:
- Initiation of a dose selection study and initial assessment of efficacy of AMP945 combined with gemcitabine/Abraxane standard of care in pancreatic cancer patients;
- Additional manufacturing work to provide clinical grade AMP945, at scale;
- Further preclinical studies of FAK inhibitors AMP945 and AMP886;
- Working capital for the advancement of corporate and business development activities.
Click here to read today’s ASX release.
Click here to view the Investor Presentation.